Pitolisant Hydrochloride and Zofran ODT
Determining the interaction of Pitolisant Hydrochloride and Zofran ODT and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%. MANAGEMENT: Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Professional:MONITOR: Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%.
MANAGEMENT: Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Generic Name: pitolisant
Brand name: Wakix
Synonyms: Pitolisant
Generic Name: ondansetron
Brand name: Zofran, Zofran ODT, Zuplenz
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pitolisant Hydrochloride-Zofran ODT Oral, Oromucosal
- Pitolisant Hydrochloride-Zofran Oral, Oromucosal
- Pitolisant Hydrochloride-Zohydro ER
- Pitolisant Hydrochloride-Zohydro ER Capsules
- Pitolisant Hydrochloride-Zoladex
- Pitolisant Hydrochloride-Zoladex (Goserelin Implant 10.8 mg)
- Zofran ODT-Pitressin
- Zofran ODT-Pitressin Injection
- Zofran ODT-Pitressin Synthetic
- Zofran ODT-Placidyl
- Zofran ODT-Plan B
- Zofran ODT-Plan B One-Step